Skip to main content

Select Drug Profiles

Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms

Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer

Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer

Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

The Role of Non-Statin Lipid-Lowering Therapy in Older Adults with ASCVD

Interview with the Innovators

A Passion for Scientific Innovation and a Company Culture That Values Customers Drive the Teams at Genmab to Discover Cutting-Edge Solutions for People with Cancer

Brad Bailey, Chris Cozic

Conference Highlights ASCO

Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer

Minimizing the Burden of Cardiovascular Disease: A Need for Lipid-Lowering Strategies Beyond Statins

Interview with the Innovators

Genmab Unleashes the Power of Strategic Alliances to Advance the Science of Therapeutic Antibodies for People with Cancer

Robyn Bilmes, Leslie Amendola

Page 13 of 244
Results 121 - 130 of 2438